Here are just a few editorial highlights from the DDNews Cancer Research News site and other online vehicles of DDNews magazine to get you acquainted with the website and show you the range of our coverage.

By Jeffrey Bouley, DDNews Chief Editor
Multiple Myeloma Research Foundation announces six new clinical trials in 2014, and Cellectar Biosciences announces IND for relapsed or refractory multiple myeloma drug
By Lloyd Dunlap, DDNews Managing Editor
With some tinkering, MIT chemists recruit anthrax to deliver anti-cancer drugs
Guest Commentary: Developing humanized cancer models for cost-effective and productive cancer drug discovery
By Dr. Jean-Pierre Wery, CrownBio
Oncology drug discovery faces one of the highest attrition rates for drug candidates in the development pipeline, largely due to efficacy issues. More relevant clinical models, ones that better reflect cancer heterogeneity and disease progression, could address this problem.
By Lloyd Dunlap, DDNews Managing Editor
FDA submission reinforces commitment to addressing significant unmet needs for patients with acute lymphoblastic leukemia, an aggressive cancer with limited treatment options
DDNews Cancer Research Exclusive: Turning an eye to TERT
By Kelsey Kaustinen, DDNews Senior Editor
As part of the TCGA initiative, researchers have discovered multiple cases of missing chromosomes in chromophobe renal cell carcinoma, as well as rearrangements in the promoter region of the TERT gene
Ventana, Bayer collaborate on ADC diagnostic test
March 2012

TUSCON, Ariz.—Ventana Medical Systems Inc. and Bayer Pharma AG have joined forces to develop a molecular companion diagnostic test to identify patients that are most likely to benefit from Bayer's antibody-drug conjugate, or ADC, cancer therapy. Per the agreement, Ventana will use its technology to analyze expression levels in certain tumor targets serving as biomarkers in clinical studies and will be responsible for developing, manufacturing and commercializing a test for one of Bayer's ADC drugs. For up to five years, either company can initiate further projects to develop diagnostic tests for additional cancer therapy drugs. Financial terms were not disclosed.
"As new biomarkers and diagnostic tests become increasingly available, they provide valuable information about potential positive recipients for these novel agents," Mara Aspinall, president of Ventana, said in a press release.


Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
© Copyright 2014 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.